These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22135208)

  • 21. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
    Gallay PA; Bobardt MD; Chatterji U; Trepanier DJ; Ure D; Ordonez C; Foster R
    PLoS One; 2015; 10(8):e0134707. PubMed ID: 26263487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.
    Ciesek S; Steinmann E; Wedemeyer H; Manns MP; Neyts J; Tautz N; Madan V; Bartenschlager R; von Hahn T; Pietschmann T
    Hepatology; 2009 Nov; 50(5):1638-45. PubMed ID: 19821520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
    Fu J; Tjandra M; Becker C; Bednarczyk D; Capparelli M; Elling R; Hanna I; Fujimoto R; Furegati M; Karur S; Kasprzyk T; Knapp M; Leung K; Li X; Lu P; Mergo W; Miault C; Ng S; Parker D; Peng Y; Roggo S; Rivkin A; Simmons RL; Wang M; Wiedmann B; Weiss AH; Xiao L; Xie L; Xu W; Yifru A; Yang S; Zhou B; Sweeney ZK
    J Med Chem; 2014 Oct; 57(20):8503-16. PubMed ID: 25310383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.
    Nguyen TH; Mentré F; Levi M; Yu J; Guedj J
    Clin Pharmacol Ther; 2014 Nov; 96(5):599-608. PubMed ID: 25166216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
    Nevers Q; Ruiz I; Ahnou N; Donati F; Brillet R; Softic L; Chazal M; Jouvenet N; Fourati S; Baudesson C; Bruscella P; Gelin M; Guichou JF; Pawlotsky JM; Ahmed-Belkacem A
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-HCV drugs in the pipeline.
    Yang PL; Gao M; Lin K; Liu Q; Villareal VA
    Curr Opin Virol; 2011 Dec; 1(6):607-16. PubMed ID: 22440918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
    Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
    Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.
    Coelmont L; Hanoulle X; Chatterji U; Berger C; Snoeck J; Bobardt M; Lim P; Vliegen I; Paeshuyse J; Vuagniaux G; Vandamme AM; Bartenschlager R; Gallay P; Lippens G; Neyts J
    PLoS One; 2010 Oct; 5(10):e13687. PubMed ID: 21060866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophilin inhibition as potential therapy for liver diseases.
    Naoumov NV
    J Hepatol; 2014 Nov; 61(5):1166-74. PubMed ID: 25048953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus.
    Roelandt P; Obeid S; Paeshuyse J; Vanhove J; Van Lommel A; Nahmias Y; Nevens F; Neyts J; Verfaillie CM
    J Hepatol; 2012 Aug; 57(2):246-51. PubMed ID: 22521345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alisporivir Improves Mitochondrial Function in Skeletal Muscle of
    Dubinin MV; Starinets VS; Talanov EY; Mikheeva IB; Belosludtseva NV; Belosludtsev KN
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy.
    Li S; Yu X; Guo Y; Kong L
    Cell Microbiol; 2012 Jul; 14(7):994-1002. PubMed ID: 22329740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms.
    Xia WL; Shen Y; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):18-22. PubMed ID: 15730912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophilin inhibitors.
    Gallay PA
    Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.
    Dash S; Prabhu R; Hazari S; Bastian F; Garry R; Zou W; Haque S; Joshi V; Regenstein FG; Thung SN
    Liver Int; 2005 Jun; 25(3):580-94. PubMed ID: 15910496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of alisporivir for the treatment of hepatitis C infection.
    Stanciu C; Trifan A; Muzica C; Sfarti C
    Expert Opin Pharmacother; 2019 Mar; 20(4):379-384. PubMed ID: 30576256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
    Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
    Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.